Alkem Laboratories Limited Appoints Srinivas Singh as Additional Director and Whole Time Director
September 14, 2022 at 04:00 am EDT
Share
Alkem Laboratories Limited at its meeting held on 14th September, 2022 has appointed Mr. Srinivas Singh (DIN: 06744441) as an Additional Director and Whole Time Director designated as an Executive Director on the Board of Directors of the Company for a period of five (5) consecutive years, with effect from 14th September, 2022 upto 13th September, 2027, subject to the approval of the shareholders of the Company. Mr. Srinivas Singh holds a Bachelor's Degree in Science. He has joined the Company in 2012 and has over 10 years of experience in pharmaceutical industry.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.